Format

Send to

Choose Destination
Semin Perinatol. 2018 Nov;42(7):425-431. doi: 10.1053/j.semperi.2018.09.004. Epub 2018 Oct 2.

Genomics, microbiomics, proteomics, and metabolomics in bronchopulmonary dysplasia.

Author information

1
Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Women and Infants Center, 176F Suite 9380, 619 South 19th Street, Birmingham, AL 35249-7335, United States. Electronic address: clal@peds.uab.edu.
2
Department of Pediatrics, Drexel University, Philadelphia, PA, United States.
3
Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Women and Infants Center, 176F Suite 9380, 619 South 19th Street, Birmingham, AL 35249-7335, United States.

Abstract

Bronchopulmonary Dysplasia (BPD) is a disorder with a multifactorial etiology and highly variable clinical phenotype. Several traditional biomarkers have been identified, but due to the complex disease phenotype, these biomarkers have low predictive accuracy for BPD. In recent years, newer technologies have facilitated the in-depth and unbiased analysis of 'big data' in delineating the diagnosis, pathogenesis, and mechanisms of diseases. Novel systems-biology based 'omic' approaches, including but not limited to genomics, microbiomics, proteomics, and metabolomics may help define the multiple cellular and humoral interactions that regulate normal as well as abnormal lung development and response to injury that are the hallmarks of BPD.

KEYWORDS:

BPD; Genetics; Metabolome; Microbiome; Proteome; Systems biology

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center